PriceTargets.com logo

ProSomnus - OSA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: ∞
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 08/5/2024 01:00 AM ET
+0 (0.00%)
Get New ProSomnus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OSA

Analyst Price Target is $2.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ProSomnus in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for OSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in ProSomnus. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/22/2024Alliance Global PartnersInitiated CoverageBuy$2.00
11/10/2023Craig HallumReiterated RatingBuy ➝ Hold$1.00
9/26/2023Roth MkmLower TargetBuy ➝ Buy$6.00 ➝ $4.00
4/18/2023Roth CapitalReiterated RatingBuy
4/3/2023Craig HallumInitiated CoverageBuy$10.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ProSomnus logo
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.41
Low: $0.02
High: $0.66

52 Week Range

Now: N/A

Volume

5 shs

Average Volume

65,686 shs

Market Capitalization

$237 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of ProSomnus?

The following Wall Street analysts have issued reports on ProSomnus in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for OSA.

What is the current price target for ProSomnus?

0 Wall Street analysts have set twelve-month price targets for ProSomnus in the last year. Their average twelve-month price target is $2.00. Alliance Global Partners has the highest price target set, predicting OSA will reach $2.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.00 for ProSomnus in the next year.
View the latest price targets for OSA.

What is the current consensus analyst rating for ProSomnus?

ProSomnus currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OSA will outperform the market and that investors should add to their positions of ProSomnus.
View the latest ratings for OSA.

What other companies compete with ProSomnus?

Other companies that are similar to ProSomnus include Dynatronics, Assure, G Medical Innovations, Nemaura Medical and Minerva Surgical. Learn More about companies similar to ProSomnus.

How do I contact ProSomnus' investor relations team?

ProSomnus' physical mailing address is Suite A-2F 555 Shihui Road Songjiang District, Shanghai F4, 201100. The company's listed phone number is 844-537-5337 and its investor relations email address is [email protected]. The official website for ProSomnus is www.ProSomnus.com. Learn More about contacing ProSomnus investor relations.